MedWatch

Bavarian Nordic on new capital raising round: Covid-19 was the decisive factor

The recent equity emission was quickly set up at Bavarian Nordic, mainly because the firm plans to power ahead with opportunities arisen during the Covid-19 pandemic. This includes the firm's coronavirus vaccine.

Bavarian Nordic EVP and CFO Henrik Juuel | Photo: PR / Bavarian Nordic

Even though Bavarian Nordic has a list of items on its shopping list after recently gaining more capital on the stock market, one factor in particular necessitated that the capital raising round had to take place exactly now.

"Our Covid-19 vaccine has been the catalyst. No doubt about it," Bavarian Nordic's Chief Financial Officer Henrik Juuel tells MedWatch and adds:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs